FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
Portfolio Pulse from Shivani Kumaresan
The FDA has granted accelerated approval for Ipsen and Genfit's new liver disease treatment, Iqirvo, to treat primary biliary cholangitis (PBC). The drug, developed by Genfit and commercialized by Ipsen, is now available for prescription in the U.S. and is expected to generate substantial milestone payments for Genfit.
June 11, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genfit's new liver disease treatment, Iqirvo, has received FDA accelerated approval, which is expected to generate substantial milestone payments for the company.
The FDA approval of Iqirvo is a significant milestone for Genfit, likely to boost its revenue through milestone payments and initial U.S. sales. This positive regulatory news is expected to have a favorable short-term impact on GNFT's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100